Industry perspective: Scale up challenges for cell & gene therapy manufacturers

In an interview hosted by Biotech Week Boston, Dr. Ger Brophy, Avantor's Executive Vice President of Biopharma Production, provided insights into cell and gene therapy industry challenges.

This informative discussion examines new trends in cell and gene therapy manufacturing development, manufacturing and supply chain are a direct reaction to the global supply chain issues we face. Learn steps biomanufacturers can take to mitigate raw material shortages and how to overcome scale up challenges faced by many in the industry.

Watch now

Hosted by

Dr. Ger Brophy

Executive Vice President, Biopharma Production

Dr. Ger Brophy is Executive Vice President, Biopharma Production at Avantor. In his current role, he is responsible for developing and implementing Avantor’s Biopharma Production offering to support current and future customer needs. Prior to joining Avantor, Dr. Brophy held a variety of research and development, strategy, advanced systems, and business development positions with GE Healthcare Life Sciences, GE Healthcare Medical Diagnostics and Amersham for nearly 30 years. Dr. Brophy earned a Bachelor of Science in biotechnology, as well as a doctorate in molecular biology from Dublin City University in Ireland.

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.